Manufacturing Round-Up: FDA Demands Meeting With Aurobindo Over Issues At Multiple Sites
Executive Summary
An FDA warning letter issued to Aurobindo highlights recurring failures over several sites, while Teva is setting up a biologics development campus in the US and Nexus is investing in sterile injectables capacity.
You may also be interested in...
Sun's Halol Site Faces FDA Action
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
Sun Site Stares At FDA Action But Dent May Be Limited
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
Piramal Looks To Build On Pharma Growth
Piramal says it is looking to build on the 17% growth in its Global Pharma business reported in its financial second quarter by investing in manufacturing expansion across differentiated product areas.